PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fcc(s), to: Mail

Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria Virginia 22313

	Alexandria, Virginia 22313-1450 or Fax (703) 746-4000							
INSTRUCTIONS: This to appropriate. All further co- indicated unless conjected	rm should be used for tra respondence including the below or directed otherwis	insmitting the ISSI Patent, advance of a in Block t, by (a	JE FEE and Pl rders and notific b) specifying a r	ACCATION FEE	if require	ed). Blocks I through 5 : I be invited to the current and/or (b) indicating a ser	should be completed where a correspondence address as wrate "FEE ADDRESS" [or	
the the neg tee neg tiertie	15. E ADOKESS (Note: Use Block 1 fi							
				Note: A carificate of mailing can only be used for domestic mailings of the Foc(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.				
				DEAC ITS OMA				
ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC. ROUTE 202-206 MAIL CODE: D303A			Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the Uni Status Postal Service with sufficient postage for first class mail in an envelo addressed to the Mail Stop ISSUE FEIS address above, or being facsing transmitted to the USPTO (703) 746-4000, on the date indicated below.				ng deposited with the United rat class mail in an envelope a heing fresionle.	
BRIDGEWATER, NJ 08807						re, Sr.	(Depozine's name)	
•							(Signery)	
				2X11/	2004	· · · · · · · · · · · · · · · · · · ·	(Doz)	
APPLICATION NO. FILING DATE			FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/087.782	10/087,782 03/05/2002		Marie Rosier			03806.0542	8826	
TITLE OF INVENTION: N						CLEIC ACIDS AND USE	S THEREOP	
APPLNLTYPE	EMALL ENTITY	ISSUE FE	EE	PUBLICATION F.	EE .	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	nonprovisional NO			5300		\$1670	02/02/2005	
EXAMINER,		ARTUN	T	CLASS-SUBCLAS	33			
HAMUD, FOZIA M		1647		435-069100				
1. Change of correspondence address or indication of "For Address" (37 CFR 1.361). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "For Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.			2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.					
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: University an artifact in identified below, so assigned data will appear on the patent. How are instantified below, so assigned data will appear on the patent.								
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filled for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filling an assignment.								
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)								
Aventis Pharma S. A. Antony, France								
Please check the appropriate	resignos caragory or catago	ries (will not be pri	ned on the pater	r): 🖵 Individua	u E Corpo	omion or other private gro	up entity Government	
4a. The following fee(s) are e	aclosed:		Payment of Fee					
A check is the amount of the foc(s) is enclosed.								
Publication Foo (No small cuttry discount permitted) Advance Order - # of Copies 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0								
THE PROPERTY OF THE PARTY OF TH		•	Deposit Account	Number V -	CON CHAR	Cooloss er oxus co	by of this form).	
	IALL ENTITY stones. See 1) 37 CFR 1.27.	b. Applicant	s no longer claimin	ng SMALL	ENTITY status. See 37 CF	R 1.27(g)(2).	
The Director of the USPTO is NOTE: The Issue Fee and Pul interest as shown by the recor	requested to apply the Issu plication Fee (if required) w ds of the United States Fate	e Foe and Publicati vill not be accepted at and Trademark (on Fee (if my) o from anyone och Office.	et than the applicat	neviously pa nt; & register	aid issue fee to the applicated atterney or agent; or the	ion identified above.	
Authorized Signsture	2			Date:	<u>. Z</u>	11/05	70087	
Typed or printed came	Joel B. Ger	man		Rogi	istration No.	48,676		
This collection of information an application. Confidentiality submitting the completed appublis form and/or suggestions that 1450, Alexandra, Virgin Alexandria, Virginia 22313-14 Under the Paperwork Reduction	is governed by 35 U.S.C. lication form to the USPTC or reducing this burden, shin 22313-1450. DO NOT S	132 and 37 CFR 1. D. Time will vary doubt be seen to the CEND FEES OR CO	14. This collecti epending upon t Chief Informatio MPLETED FO	on is estimated to the individual case. A Officer, U.S. Patellines TO THIS AC	Any comments and Trace DDRESS. SI	ates to complete, including tonus on the amount of time demark Office, U.S. Department of the END TO: Commissioner for	g gathering, preparing, and go you require to complete furnam of Commerce, P.O. or Patents, P.O. Box 1450,	

PTOL-85 (Rev. 09/04) Approved for use through 04/30/2007.

03/11/2005 AKELLEY [:] 0(OMB 0651-0033" U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PAGE 4/4 * RCVD AT 2/11/2005 3:02:48 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/0 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):01-56